Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.53 |
| ▸ | RXRB | P28702 | 6/20 | 0.53 |
| ▸ | RXRG | P48443 | 5/20 | 0.53 |
| ▸ | CYP26B1 | Q9NR63 | 8/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 7/20 | 0.50 |
| ▸ | RARA | P10276 | 3/20 | 0.44 |
| ▸ | RARB | P10826 | 3/20 | 0.44 |
| ▸ | RARG | P13631 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552820 | 0.88 | RXRA (0.41) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL2238564 | 0.86 | RXRA (0.42) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL13318274 | 0.86 | RXRA (0.42) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL7947551 | 0.86 | RXRA (0.46) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL11240978 | 0.85 | CYP26B1 (0.51) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL3176733 | 0.82 | RXRA (0.54) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL9860525 | 0.81 | RARB (0.58) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL14286073 | 0.80 | RXRA (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL2095481 | 0.80 | RXRA (0.57) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL694638 | 0.80 | RXRA (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617880-B2 | Compounds for use in catalyst compositions for the production of polyolefins | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2026-05-05 | — | — | US | disclosed |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| EP-3844196-B1 | SUBSTITUTED BIS-2-INDENYL METALLOCENE COMPOUNDS | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2023-03-08 | — | — | EP | disclosed |
| US-20220332861-A1 | COMPOUNDS FOR USE IN CATALYST COMPOSITIONS FOR THE PRODUCTION OF POLYOLEFINS | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2022-10-20 | — | — | US | disclosed |
| US-11472895-B2 | Substituted bis-2-indenyl metallocene compounds | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2022-10-18 | — | — | US | disclosed |
| EP-4028437-A1 | COMPOUNDS FOR USE IN CATALYST COMPOSITIONS FOR THE PRODUCTION OF POLYOLEFINS | SABIC Global Technologies, B.V. (NL) | 2022-07-20 | — | — | EP | disclosed |
| EP-3997089-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | University Of Virginia Patent Foundation (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114364707-A | Compounds for use in catalyst compositions for the production of polyolefins | SABIC环球技术有限责任公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-5248823-A | Diphenylheteroalkyl derivatives, the preparation thereof and drugs and cosmetics prepared therefrom | BASF AKTIENGESELLSCHAFT (DE) | 1993-09-28 | — | — | US | disclosed |
| EP-0386452-B1 | DIPHENYL HETEROALKYL DERIVATIVES, THEIR PREPARATION AND MEDICINAL AND COSMETIC PREPARATIONS PREPARED THEREFROM | BASF Aktiengesellschaft (DE) | 1993-09-22 | — | — | EP | disclosed |
| EP-0382078-B1 | AROMATIC KETO COMPOUNDS, THEIR PREPARATION AND MEDICINAL AS WELL AS COSMETIC PREPARATIONS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1993-09-22 | — | — | EP | disclosed |
| EP-0555265-A1 | BICYCLO-COMPOUNDS WITH AN ANTI-SEBORRHOEIC ACTION | Henkel Kommanditgesellschaft auf Aktien (DE) | 1993-08-18 | — | — | EP | disclosed |
| US-5225601-A | Sulfur containing compounds for skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1993-07-06 | — | — | US | disclosed |
| US-5194664-A | Aromatic keto compounds, the preparation thereof, and drugs and cosmetics containing these | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-16 | — | — | US | disclosed |
| WO-1992006946-A1 | BICYCLO-COMPOUNDS WITH AN ANTI-SEBORRHOEIC ACTION | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1992-04-30 | — | — | WO | disclosed |
| US-5087743-A | Treatment of skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1992-02-11 | — | — | US | disclosed |
| EP-0386452-A1 | Diphenyl heteroalkyl derivatives, their preparation and medicinal and cosmetic preparations prepared therefrom | BASF Aktiengesellschaft (DE) | 1990-09-12 | — | — | EP | disclosed |
| EP-0382078-A1 | Aromatic keto compounds, their preparation and medicinal as well as cosmetic preparations containing them | BASF Aktiengesellschaft (DE) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617880-B2 | Compounds for use in catalyst compositions for the production of polyolefins | PRMT5, CBR3, MET | RXRA 2035/4885RXRB 1751/4885RXRG 1855/4885 |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | RXRA 3114/4885RXRB 2805/4885RXRG 2779/4885 |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | RXRA 3114/4885RXRB 2805/4885RXRG 2779/4885 |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | RXRA 3114/4885RXRB 2805/4885RXRG 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.